0000929638-24-001751.txt : 20240509 0000929638-24-001751.hdr.sgml : 20240509 20240509160537 ACCESSION NUMBER: 0000929638-24-001751 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 EFFECTIVENESS DATE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 24930438 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: Advaxis, Inc. DATE OF NAME CHANGE: 20050105 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 15-12G 1 form1512.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 FORM 15
 
 
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number 001-36138

 

 AYALA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)



9 Deer Park Drive, Suite K-1
Monmouth Junction, NJ 08852
Telephone: (609) 452-9813
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
None
(Title of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
 
☒
Rule 12g-4(a)(2)
 
☐
Rule 12h-3(b)(1)(i)
 
☒
Rule 12h-3(b)(1)(ii)
 
☐
Rule 15d-6
 
☐
Rule 15d-22(b)
 
☐

Approximate number of holders of record as of the certification or notice date: 136.
 
Pursuant to the requirements of the Securities Exchange Act of 1934 Ayala Pharmaceuticals, Inc., has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
 
 
 
 
 
 
 
 
Date: May 9, 2024
 
 
 
Ayala Pharmaceuticals, Inc.
 
 
 
 
 
 
 
 
By:
 
/s/ Kenneth Berlin
 
 
 
 
Name:
 
Kenneth Berlin
 
 
 
 
Title:
 
President and Chief Executive Officer